-
Something wrong with this record ?
Differential expression and prognostic role of selected genes in colorectal cancer patients
P. Pitule, O. Vycital, J. Bruha, P. Novak, P. Hosek, V. Treska, I. Hlavata, P. Soucek, M. Kralickova, V. Liska,
Language English Country Greece
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12025
MZ0
CEP Register
NT14329
MZ0
CEP Register
Digital library NLK
Full text - Article
Full text - Article
Source
Source
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
PubMed
24222123
Knihovny.cz E-resources
- MeSH
- Chemotherapy, Adjuvant MeSH
- Colon metabolism pathology MeSH
- Colorectal Neoplasms drug therapy genetics mortality pathology MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphatic Metastasis MeSH
- RNA, Messenger genetics MeSH
- Survival Rate MeSH
- Biomarkers, Tumor genetics MeSH
- Follow-Up Studies MeSH
- Palliative Care MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Prognosis MeSH
- Aged MeSH
- Neoplasm Grading MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
AIM: Colorectal cancer (CRC) is one of the most common malignant diseases. The aim of our study was to describe the expression status of 12 selected candidate genes, by comparing paired samples of healthy colon mucosa and tumour tissues and to correlate obtained data with clinical and pathological features, with the goal of revealing associations for individual gene expressions and tumour behaviour. MATERIALS AND METHODS: Samples from 53 patients with CRC were analyzed. Patients were divided into two groups based on the presence or absence of distant metastases at the time of primary tumour surgery. Expression levels were assessed by quantitative real-time polymerase chain reaction. RESULTS: We found changes in the expression of 10 out of 12 analyzed genes. Four genes were significantly up-regulated in tumour tissues: leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; p<0.001), collagen triple helix repeat containing 1 (CTHRC1; p<0.001), visinin-like 1 (VSNL1; p<0.001) and versican (VCAN; p=0.001). Six genes were down-regulated: destrin (DSTN; p=0.004), mesoderm induction early response 1, family member 3 (MIER3; p<0.001), acyl-CoA synthetase long-chain family member 5 (ACSL5; p=0.002), mitogen-activated protein kinase 1/ERK (MAPK1; p<0.001), claudin 23 (CLDN23; p<0.001) and solute carrier family 26 (sulfate transporter), member 2 (SLC26A2; p<0.001). We recorded longer overall survival (OS) in the group of patients with higher expression of VSNL1 (p=0.032). Patients with more pronounced down-regulation of CLDN23 had shorter OS (p=0.045). In the group of patients without distant metastases, longer OS and disease-free interval (DFI) were found for patients with higher SLC26A2 expression in tumour tissues (p=0.036 and p=0.011, respectively). In the same group, lower expression of VSNL1 in healthy tissue corresponded to a longer DFI (p=0.020), smaller decrease of SLC26A2 and ACSL5 meant longer DFI (p=0.041 and p=0.040, respectively), as did greater increase of LGR5 expression (p=0.026). CONCLUSION: We identified differences in the expression of 10 genes in colorectal cancer tissue compared to healthy colon mucosa, and found prognostic significance for these changes which could be used for the development of a disease risk scoring system.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14050754
- 003
- CZ-PrNML
- 005
- 20190710101647.0
- 007
- ta
- 008
- 140401s2013 gr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)24222123
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Pitule, Pavel $7 xx0170503
- 245 10
- $a Differential expression and prognostic role of selected genes in colorectal cancer patients / $c P. Pitule, O. Vycital, J. Bruha, P. Novak, P. Hosek, V. Treska, I. Hlavata, P. Soucek, M. Kralickova, V. Liska,
- 520 9_
- $a AIM: Colorectal cancer (CRC) is one of the most common malignant diseases. The aim of our study was to describe the expression status of 12 selected candidate genes, by comparing paired samples of healthy colon mucosa and tumour tissues and to correlate obtained data with clinical and pathological features, with the goal of revealing associations for individual gene expressions and tumour behaviour. MATERIALS AND METHODS: Samples from 53 patients with CRC were analyzed. Patients were divided into two groups based on the presence or absence of distant metastases at the time of primary tumour surgery. Expression levels were assessed by quantitative real-time polymerase chain reaction. RESULTS: We found changes in the expression of 10 out of 12 analyzed genes. Four genes were significantly up-regulated in tumour tissues: leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; p<0.001), collagen triple helix repeat containing 1 (CTHRC1; p<0.001), visinin-like 1 (VSNL1; p<0.001) and versican (VCAN; p=0.001). Six genes were down-regulated: destrin (DSTN; p=0.004), mesoderm induction early response 1, family member 3 (MIER3; p<0.001), acyl-CoA synthetase long-chain family member 5 (ACSL5; p=0.002), mitogen-activated protein kinase 1/ERK (MAPK1; p<0.001), claudin 23 (CLDN23; p<0.001) and solute carrier family 26 (sulfate transporter), member 2 (SLC26A2; p<0.001). We recorded longer overall survival (OS) in the group of patients with higher expression of VSNL1 (p=0.032). Patients with more pronounced down-regulation of CLDN23 had shorter OS (p=0.045). In the group of patients without distant metastases, longer OS and disease-free interval (DFI) were found for patients with higher SLC26A2 expression in tumour tissues (p=0.036 and p=0.011, respectively). In the same group, lower expression of VSNL1 in healthy tissue corresponded to a longer DFI (p=0.020), smaller decrease of SLC26A2 and ACSL5 meant longer DFI (p=0.041 and p=0.040, respectively), as did greater increase of LGR5 expression (p=0.026). CONCLUSION: We identified differences in the expression of 10 genes in colorectal cancer tissue compared to healthy colon mucosa, and found prognostic significance for these changes which could be used for the development of a disease risk scoring system.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a kolon $x metabolismus $x patologie $7 D003106
- 650 _2
- $a kolorektální nádory $x farmakoterapie $x genetika $x mortalita $x patologie $7 D015179
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a paliativní péče $7 D010166
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a messenger RNA $x genetika $7 D012333
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vyčítal, Ondřej, $d 1985- $7 mzk2016922773
- 700 1_
- $a Brůha, Jan, $d 1984- $7 mzk2016922447
- 700 1_
- $a Novák, Petr, $d 1968- $7 xx0079055
- 700 1_
- $a Hošek, Petr $7 xx0224573
- 700 1_
- $a Třeška, Vladislav, $u - $d 1957- $7 jn20000402436
- 700 1_
- $a Hlavatá, Ivona $u - $7 _AN063454
- 700 1_
- $a Souček, Pavel $u - $7 xx0060511
- 700 1_
- $a Králíčková, Milena, $u - $d 1972- $7 xx0069996
- 700 1_
- $a Liška, Václav, $u - $d 1978- $7 xx0073943
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 33, č. 11 (2013), s. 4855-4865
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24222123 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20190710101846 $b ABA008
- 999 __
- $a ok $b bmc $g 1017890 $s 849334
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 33 $c 11 $d 4855-4865 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- GRA __
- $a NT12025 $p MZ0
- GRA __
- $a NT14329 $p MZ0
- LZP __
- $a Pubmed-20140401